Publications by authors named "Zureik M"
Background: Since 2020, trastuzumab deruxtecan (T-DXd) has been used in France for patients with previously treated human epidermal growth factor receptor 2 (HER2)-positive or HER2-low metastatic breast cancer (mBC). We aimed to describe the clinical characteristics, outcomes, and potential toxicities among patients receiving T-DXd for HER2-positive and HER2-low mBC.
Patients And Methods: Using the French National Health Data System (SNDS), we identified patients who initiated T-DXd for mBC from 30 September 2020 to 30 September 2023.
Background: The lack of evidence under routine clinical settings limited the widespread adoption of adalimumab biosimilars for psoriasis treatment.
Objective: This study compared the drug survival and safety of adalimumab biosimilars to Humira for psoriasis treatment.
Methods: We conducted a prevalent new-user cohort study using data from the French National Health Data System (SNDS), the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), and the Spanish Registry of Systemic Therapy in Psoriasis (BIOBADADERM).
Background And Purpose: Chlormadinone acetate (CMA) is a synthetic progestin for which cases of intracranial meningioma have been reported following prolonged exposure.
Method: An observational cohort study was conducted based on the French national health data system. Women aged 10-70 years and who started CMA between 2007 and 2017 were included.
Introduction: Trastuzumab deruxtecan (T-DXd) has been approved for human epidermal growth factor receptor 2-positive locally advanced or metastatic gastric and gastroesophageal junction (HER2+ mG/GEJ) cancer since July 2022 in France, through an accelerated approval. The aim of this study was to evaluate its real-world use.
Methods: We characterized T-DXd users treated for HER2+ mG/GEJ cancer using data from the French National Health Insurance database.
Myocarditis is the most salient serious adverse event following messenger RNA-based Covid-19 vaccines. The highest risk is observed after the second dose compared to the first, whereas the level of risk associated with more distant booster doses seems to lie in between. We aimed to assess the relation between dosing interval and the risk of myocarditis, for both the two-dose primary series and the third dose (first booster).
View Article and Find Full Text PDFBackground: COVID-19 vaccination has been inconsistently associated with an increased risk of heavy menstrual bleeding in previous studies. This study aimed to assess the risk of heavy menstrual bleeding requiring hospital care following COVID-19 vaccination according to the number of doses received and the time elapsed since vaccination.
Methods: Using comprehensive data of the French National Health Data System, we carried out a case-control study.
Importance: Although patients with myocarditis after COVID-19 mRNA vaccination appear to have a good prognosis near hospital discharge, their longer-term prognosis and management remain unknown.
Objective: To study the cardiovascular complications of post-COVID-19 mRNA vaccination myocarditis and other types of myocarditis during an 18-month follow-up, as well as disease management based on a study of the frequency of medical procedures and drug prescriptions.
Design, Setting, And Participants: In this cohort study based on the French National Health Data System, all individuals aged 12 to 49 years hospitalized for myocarditis in France between December 27, 2020, and June 30, 2022, were identified.
Article Synopsis
- - The study aimed to identify risk factors for early childhood physical abuse (CPA) in France by analyzing data from infants born between 2010 and 2019, focusing on maternal, prenatal, and postnatal factors.
- - Out of nearly 7 million infants studied, about 3,000 were diagnosed with early CPA, with significant risk factors including low financial resources, young maternal age, substance abuse, intimate partner violence, and various health issues.
- - Findings are intended to guide better understanding of CPA and to develop targeted prevention strategies that identify high-risk parents for effective intervention.
Background: In spite of major effectiveness, a residual risk after COVID-19 primary vaccination was identified, in particular, for vulnerable individuals of advanced age or with comorbidities. Less is known about the Omicron period in people protected by a booster dose. We aimed to identify the characteristics associated with severe COVID-19 during the Omicron period in a population that had received a booster dose in France and to compare differences with the previous periods of the pandemic.
View Article and Find Full Text PDFBackground: Nomegestrol acetate (NOMAC) is a synthetic potent progestogen. This study aimed to assess the risk of intracranial meningioma associated with the prolonged use of NOMAC.
Methods: Observational cohort study using SNDS data (France).
Article Synopsis
- The study aimed to compare the risk of gastrointestinal perforation (GIP) between patients using JAK inhibitors (like tofacitinib and baricitinib) and those using the TNF inhibitor adalimumab in individuals with rheumatic diseases.
- Researchers analyzed data from a large cohort (39,758 patients) sourced from the French national health database from July 2017 to December 2021, tracking GIP occurrences until May 2022.
- Results showed that the incidence rates of GIP were similar between the two groups, with no significant difference in risk levels, suggesting that both treatments are comparable concerning this rare but serious side effect.
Importance: Cancer is a leading cause of death among children worldwide. Treatments used for medically assisted reproduction (MAR) are suspected risk factors because of their potential for epigenetic disturbance and associated congenital malformations.
Objective: To assess the risk of cancer, overall and by cancer type, among children born after MAR compared with children conceived naturally.
Objective: To assess the risk of intracranial meningioma associated with the use of selected progestogens.
Design: National case-control study.
Setting: French National Health Data System (ie, ).
Article Synopsis
- The study aimed to compare the persistence and safety of biosimilar medications versus their originator counterparts for infliximab, etanercept, and adalimumab in various medical conditions.
- Researchers utilized extensive data from the French National Health Data System, tracking nearly 87,000 patients from the launch of biosimilars in 2015, 2016, and 2018 until June 2021, with a follow-up period of one year.
- Results indicated no significant difference in treatment discontinuation rates or safety events, suggesting biosimilars are as safe and effective as their originators across all licensed indications.
Introduction: Previous studies have identified an interaction between protein kinase inhibitors (PKIs) and proton pump inhibitors (PPIs) in patients with lung cancer. This type of interaction may reduce the efficacy of PKIs. However, the effect of PKI-PPI interaction on patient mortality remains controversial.
View Article and Find Full Text PDFBackground: Proton pump inhibitors (PPIs) are largely used in older adults and data are needed in off-label indications, such as the prevention of upper gastrointestinal bleeding (UGIB) in patients receiving oral anticoagulants (OACs). This study aimed to assess whether PPIs reduce the risk of UGIB in patients initiating oral anticoagulation.
Methods: We conducted a longitudinal study based on the French national health database.
Importance: Solid organ transplant recipients are at high risk of severe infection with SARS-CoV-2 compared with the general population. However, factors associated with COVID-19-related severity in this population are still insufficiently explored in the literature.
Objective: To examine which health conditions and immunosuppressive drugs for preventing graft rejection are associated with the risk of COVID-19-related hospitalization in solid organ transplant recipients.
Article Synopsis
- * It involved a case-control analysis of 38,839 hospitalized COVID-19 patients matched with 377,653 controls, revealing that primary vaccination offers 45% protection, and booster doses can provide varying levels of effectiveness depending on the time since administration.
- * Results indicated that while primary vaccination is beneficial, booster effectiveness declines over time, with significant protection seen within two months post-booster but dropping significantly after six months, and prior SARS-CoV-2 infection also offers long-lasting protection.
Background And Objectives: Guillain-Barré syndrome (GBS) has been inconsistently associated with some coronavirus disease 2019 (COVID-19) vaccines. We aimed to quantify the risk of GBS according to the type of COVID-19 vaccine in a large population.
Methods: Using the French National Health Data System linked to the COVID-19 vaccine database, we analyzed all individuals aged 12 years or older admitted for GBS from December 27, 2020, to May 20, 2022.
Article Synopsis
- This study examines antibiotic use in pregnant women, revealing that 35.8% of pregnancies experienced antibiotic exposure, primarily from amoxicillin.
- It found that antibiotic prescriptions were less frequent during pregnancy compared to the year before and after pregnancy, likely due to careful consideration of risks and benefits.
- Factors such as social deprivation, smoking-related health issues, and chronic diseases were linked to a higher likelihood of filling antibiotic prescriptions during pregnancy.
Importance: Proton pump inhibitor (PPI) use may lead to infections through alteration of the microbiota or direct action on the immune system. However, only a few studies were conducted in children, with conflicting results.
Objective: To assess the associations between PPI use and serious infections in children, overall and by infection site and pathogen.
Background: Many biologics are available for psoriasis and have been compared in real-life studies based on their persistence (i.e. time between initiation and discontinuation).
View Article and Find Full Text PDFArticle Synopsis
- Psoriasis is a long-lasting skin condition, and adalimumab is a treatment that used to be very expensive, but now cheaper versions called biosimilars are available after the original product's patent ran out.
- This study aims to compare how well the biosimilars work and how safe they are compared to the original adalimumab by looking at real patient data from different countries.
- The researchers will share their findings in scientific journals and at dermatology conferences by the end of 2023, following ethical guidelines.
No study has yet investigated if a severe SARS-CoV-2 infection represents a marker of an undiagnosed cancer. This population-based study, using the SNDS database, identified from 02/15/2020 to 08/31/2021, 41,302 individuals hospitalized in intensive care unit due to SARS-CoV-2 (ICU-gr) and 713,670 control individuals not hospitalized for SARS-CoV-2 (C-gr). Individuals were matched according to year of birth, sex and French department.
View Article and Find Full Text PDFAim Of The Study: To assess the prevalence of potentially inappropriate medications (PIMs) and polypharmacy in adults aged 75 years and over in France in 2019 based on data from the French health insurance claims database, at the national level and by region.
Methods: We conducted a cross-sectional study in French adults aged 75 years or over in 2019. We assessed the prevalence of seventeen PIM criteria adapted from the 2015 Beers and STOPP lists, as well as cumulative polypharmacy.